BIOCENTURY reported that peptides-related and RP1 advisory committees could test FDA credibility after seven compounding panel members with ties to peptide businesses were identified, while the RP1 roster reportedly remains undisclosed. The situation centers on how conflict-of-interest and transparency expectations intersect with decisions that affect compounding oversight. For the industry, the episode highlights how regulatory governance details—who sits on which panels and what relationships are disclosed—can influence stakeholder confidence even when technical reviews continue.